Market Overview

AbCellera Acquires Lineage Biosciences


AbCellera expands its antibody discovery capabilities by capturing
foundational repertoire sequencing technology from immune profiling

AbCellera Biologics Inc., a technology
leader in therapeutic antibody discovery, has acquired Lineage
Biosciences in an all-stock transaction. Through the acquisition,
AbCellera expands its capabilities in antibody discovery and vaccine
research by obtaining exclusive rights to foundational technology for
immune repertoire sequencing.

Lineage Biosciences, a Palo Alto-based start-up, was founded based on
technology for the profiling of antibody responses using next-generation
sequencing of immunoglobulin genes (Ig-SEQ). Ig-SEQ enables deep
analysis of antibodies generated by natural immune responses during
infection, autoimmune disease, cancer, immunization, and vaccination.

Ig-SEQ was developed by Professor Stephen Quake's research group at
Stanford University, which licenses the technology to Lineage
Biosciences. Ig-SEQ has been widely adopted as a platform for basic and
translational immunology research and is increasingly being applied in
industry to develop vaccines and to accelerate antibody discovery. Deep
profiling of antibody repertoires complements the unique functional
information obtained from AbCellera's single B cell discovery platform,
increasing the diversity of antibodies identified and enabling
comprehensive analysis of immune responses over time.

"Through this acquisition, AbCellera has expanded its intellectual
property estate into an important area. The addition of repertoire
sequencing is strategic and complements our core microfluidic
single-cell screening platform. It reinforces our technology advantage
in antibody discovery and vaccine research," commented Dr. Carl Hansen,
CEO of AbCellera.

About AbCellera Biologics Inc.

AbCellera is a privately held company that engages in partnerships to
discover and develop next-generation therapeutic antibodies. AbCellera's
single-cell platform integrates end-to-end capabilities for therapeutic
antibody discovery through a combination of technologies including
proprietary immunizations, microfluidics, high-throughput imaging,
genomics, computation, and laboratory automation. Ultra-deep screening
of single B cells allows unprecedented access to natural immune
responses, enabling rapid isolation of large and diverse panels of
high-quality lead antibodies from any species, including humans.

Find a complete list of news announcements on AbCellera's online news
, on LinkedIn
and on Twitter

View Comments and Join the Discussion!